Benzodiazepines — a class of central nervous system depressants that includes diazepam, alprazolam, clonazepam, lorazepam, temazepam, and chlordiazepoxide — are among the most widely prescribed medications in the United States. They are prescribed legitimately for anxiety disorders, panic disorder, alcohol withdrawal, seizure management, and short-term insomnia. At the same time, they carry a meaningful risk of physical dependence, and long-term or high-dose use can lead to a substance use disorder that requires careful, medically supervised care to address.

In Tennessee, where the broader landscape of prescription drug misuse has drawn sustained attention from public health agencies, benzodiazepine-related harms present a distinct clinical picture that is often different from opioid-related concerns. Unlike opioid withdrawal, benzodiazepine withdrawal can be life-threatening if not managed properly — a fact that makes the availability of qualified treatment programs across the state especially important.

This resource explains how benzodiazepines work, what distinguishes physical dependence from a substance use disorder, what the current evidence says about treatment, and where people across Tennessee — from Nashville and Memphis to Knoxville and Chattanooga — can access that care.

How Benzodiazepines Act on the Brain

Benzodiazepines bind to GABA-A receptors — the brain’s primary inhibitory receptors — and enhance the effect of gamma-aminobutyric acid (GABA), the neurotransmitter that slows neural activity. The result is a reduction in anxiety, a lowering of muscle tension, anticonvulsant effects, and, at higher doses, sedation. These are precisely the properties that make benzodiazepines clinically useful; they are also what drives the brain’s adaptation over time.

With repeated use, the brain compensates for the artificially elevated GABA activity by downregulating receptor sensitivity and reducing its own GABA production. When the drug is stopped or the dose is reduced, the inhibitory signal that benzodiazepines were providing disappears — but the brain’s compensatory adjustments remain, producing a state of central nervous system hyperexcitability. That neuroadaptation is the physiological root of both withdrawal symptoms and the medical danger they carry.

Long-Acting vs. Short-Acting: Why Half-Life Matters for Withdrawal

Not all benzodiazepines behave the same way in the body. Their elimination half-lives vary dramatically, and this directly shapes the timing, severity, and duration of withdrawal symptoms — and therefore the structure of any tapering protocol.

Clinicians managing benzodiazepine withdrawal typically convert the person’s current drug to an equivalent dose of a longer-acting agent — most often diazepam or clonazepam — then taper that dose gradually over weeks to months depending on the duration and dose of prior use. The Ashton Manual, developed by British pharmacologist Professor Heather Ashton, remains an influential resource among clinicians for structuring individualized taper schedules, though it is always implemented under medical supervision. You can access the Ashton Manual online for reference, but any taper should be guided by a qualified healthcare provider.

Physical Dependence vs. Benzodiazepine Use Disorder: An Important Distinction

One of the most significant sources of confusion — and stigma — around benzodiazepines is the conflation of physical dependence with a substance use disorder. These are related but distinct clinical concepts.

NIDA language guidelines emphasize using non-stigmatizing, person-first language — saying “a person with a benzodiazepine use disorder” rather than “a benzo addict.” This matters clinically because stigma is one of the most significant barriers to treatment-seeking, and people who feel judged are less likely to disclose their use to healthcare providers or ask for help. Using accurate, respectful language is part of effective care.

The Medical Risks of Benzodiazepine Withdrawal

Withdrawal symptoms can range from mild anxiety and insomnia through to severe neurological events. Common signs include the following, though severity depends heavily on the individual’s history of use:

Who Is Most Likely to Develop Benzodiazepine Dependence

Research consistently identifies several factors that increase the likelihood of developing physical dependence or a use disorder with benzodiazepines. Understanding these is useful both for individuals and for the clinicians and loved ones supporting them.

It is worth noting that many people who develop physical dependence on benzodiazepines first received them through legitimate medical care. Their situation is distinct from someone who sought the drug out non-medically — but the clinical need for a managed taper and supportive treatment is identical. Both deserve compassionate, non-judgmental care.

The Particular Danger of Benzodiazepines Combined with Opioids

Tennessee has been disproportionately affected by opioid overdose deaths, and the co-prescription and co-use of benzodiazepines with opioids dramatically amplifies overdose risk. Both drug classes depress the central nervous system — and when combined, the respiratory depression each produces is compounded rather than simply additive. NIDA data indicates that more than 30% of opioid overdose fatalities also involve a benzodiazepine.

The FDA issued a black box warning in 2016 — the agency’s most serious cautionary label — about the risks of combining opioids and benzodiazepines. Tennessee’s own prescription drug monitoring program (PDMP), the Controlled Substance Monitoring Database (CSMD), allows prescribers and pharmacists to check a patient’s prescription history precisely to flag this kind of dangerous co-prescribing pattern.

For people currently managing dependence on both opioids and benzodiazepines, treatment planning requires careful coordination. Clinicians generally address the substance that carries the greater acute medical risk first, but this is always an individualized decision. Programs offering medically supervised detox and polysubstance treatment are the most appropriate settings for this complex clinical picture.

Treatment for Benzodiazepine Use Disorder and Dependence

Effective treatment for benzodiazepine dependence and use disorder is available across Tennessee. The structure of that treatment depends on the severity of dependence, whether other substances are involved, the person’s medical and psychiatric history, and their living situation and support network.

Evidence-Based Therapies Used in Benzodiazepine Treatment

Several behavioral therapies have a strong evidence base for anxiety disorders and substance use disorders, making them particularly relevant for benzodiazepine use disorder. The most widely supported approaches include:

Support Groups for Benzodiazepine Use and Dependence

Peer support plays a meaningful role in long-term recovery. Several organizations offer specialized support for people navigating benzodiazepine dependence — a population that has historically found some traditional recovery fellowships less attuned to the unique experience of prescription-drug dependence following legitimate medical use.

Specific Benzodiazepines: Explore by Drug Name

Each benzodiazepine has distinct pharmacological properties that affect its clinical use, abuse potential, and the specifics of withdrawal management. The following pages provide substance-specific information:

Also see related sedative-hypnotic classes: Barbiturates and Z-Drugs (Ambien, Lunesta, Sonata).

Find Benzodiazepine Treatment Across Tennessee

Treatment centers across Tennessee offer medically supervised programs for benzodiazepine dependence and use disorder. Use the location links below to explore programs in your area of the state.

References and Citations

1. National Institute on Drug Abuse (NIDA). Benzodiazepines and Opioids. U.S. Department of Health and Human Services. Available at: nida.nih.gov
2. NIDA. Words Matter: Terms to Use and Avoid When Talking About Addiction. Available at: nida.nih.gov/nidamed
3. Bounds CG, Nelson VL. Benzodiazepines. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: ncbi.nlm.nih.gov/books/NBK562215
4. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health. U.S. DHHS. Available at: samhsa.gov
5. Ashton H. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Newcastle University, 2002 (revised 2011). Available at: benzo.org.uk/manual
6. U.S. Food and Drug Administration (FDA). Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines. 2016. Available at: fda.gov
7. Tennessee Department of Mental Health and Substance Abuse Services. Controlled Substance Monitoring Database (CSMD). Available at: tn.gov
8. Lader M. Benzodiazepine harm: how can it be reduced? British Journal of Clinical Pharmacology. 2014;77(2):295–301. doi: 10.1111/j.1365-2125.2012.04418.x
9. SMART Recovery. About SMART Recovery. Available at: smartrecovery.org
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Publishing; 2013.

This content is intended for informational purposes only and does not constitute medical advice. If you are experiencing symptoms of benzodiazepine withdrawal, please seek immediate medical attention. Treatment listings on this site are independently verified and are not endorsements of any specific provider.